The United States market has remained flat over the past week but has experienced a robust 39% increase over the past year, with earnings projected to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an environment poised for continued expansion.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 21.08% | 28.73% | ★★★★★★ |
Sarepta Therapeutics | 23.80% | 44.01% | ★★★★★★ |
TG Therapeutics | 28.54% | 43.77% | ★★★★★★ |
Invivyd | 42.91% | 70.39% | ★★★★★★ |
Ardelyx | 27.19% | 66.44% | ★★★★★★ |
Amicus Therapeutics | 20.26% | 62.89% | ★★★★★★ |
AsiaFIN Holdings | 60.53% | 81.55% | ★★★★★★ |
Travere Therapeutics | 29.24% | 70.77% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Zai Lab Limited is a biopharmaceutical company that focuses on developing and commercializing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience with a market cap of approximately $3.18 billion.
Operations: Zai Lab generates revenue primarily from its biotechnology segment, which reported $322.71 million. The company is involved in the development and commercialization of therapies across various therapeutic areas.
Zai Lab is distinguishing itself in the biotech landscape, notably through its innovative approach in drug development, as evidenced by the promising results of ZL-1310 for treating small cell lung cancer. The firm's recent presentation at the ENA Symposium showcased a 74% objective response rate among evaluated patients, underscoring its potential to address significant unmet medical needs. Financially, Zai Lab has demonstrated robust revenue growth of 33.1% annually, outpacing the US market average of 8.9%. Despite current unprofitability, projections indicate a sharp turnaround with earnings expected to surge by 65.37% per year. This trajectory is supported by substantial R&D investments aimed at pioneering treatments that could revolutionize therapeutic standards and patient outcomes in oncology and beyond.
Review our historical performance report to gain insights into Zai Lab's's past performance.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Cadence Design Systems, Inc. is a global provider of software, hardware, services, and reusable integrated circuit (IC) design blocks with a market capitalization of approximately $70.45 billion.
Operations: Cadence generates revenue primarily from its CAD/CAM software segment, which accounts for $4.16 billion. The company's business model focuses on offering a comprehensive suite of design tools and solutions for integrated circuits, catering to a global clientele in the semiconductor industry.
Cadence Design Systems, amid a flurry of fixed-income offerings totaling nearly $3 billion, showcases a strategic approach to bolstering its financial architecture for sustained innovation and growth. With an R&D investment intensity that starkly contrasts many peers, Cadence not only prioritizes technological advancement but also aligns with market demands—evident from its 12.3% expected annual revenue growth outpacing the US market's 8.9%. Furthermore, the company’s anticipated earnings growth of 16.3% underscores its operational efficacy and potential to leverage industry shifts towards more sophisticated design software solutions. This robust financial health combined with strategic capital maneuvers positions Cadence favorably within the competitive tech landscape as it continues to navigate through dynamic market conditions and evolving technological frontiers.
Examine Cadence Design Systems' past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pegasystems Inc. is a company that develops, markets, licenses, hosts, and supports enterprise software globally with a market cap of $6.86 billion.
Operations: Pegasystems generates revenue primarily through its software and programming segment, amounting to $1.48 billion. The company operates across various regions, including the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
Pegasystems, transitioning into profitability this year, reflects a strategic pivot with its R&D spending aligning closely with industry demands for cloud-based solutions. With an impressive 23.9% forecast in earnings growth annually outstripping the US market's 15.1%, and a more modest revenue growth prediction of 5.9%, the company is positioning itself strategically within the tech landscape. Recent shifts include appointing a new Chief Cloud Officer to enhance Pega Cloud offerings, signaling robust adaptation to evolving digital needs while addressing the growing demand for generative AI and cloud services as outlined by recent executive movements and product expansions.
Explore historical data to track Pegasystems' performance over time in our Past section.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:ZLAB NasdaqGS:CDNS and NasdaqGS:PEGA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。